Bristol-Myers Squibb [BMY] vs Gilead Sciences [GILD] Detailed Stock Comparison

Bristol-Myers Squibb Company

NYSE
Loading...

Gilead Sciences, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Bristol-Myers Squibb Company wins in 12 metrics, Gilead Sciences, Inc. wins in 9 metrics, with 0 ties. Bristol-Myers Squibb Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bristol-Myers Squibb Company Gilead Sciences, Inc. Better
P/E Ratio (TTM) 17.06 19.66 Bristol-Myers Squibb Company
Price-to-Book Ratio 6.51 7.29 Bristol-Myers Squibb Company
Debt-to-Equity Ratio 254.98 112.92 Gilead Sciences, Inc.
PEG Ratio 0.01 0.85 Bristol-Myers Squibb Company
EV/EBITDA 8.20 12.44 Bristol-Myers Squibb Company
Profit Margin (TTM) 14.64% 28.90% Gilead Sciences, Inc.
Operating Margin (TTM) 28.16% 37.38% Gilead Sciences, Inc.
EBITDA Margin (TTM) 28.16% 37.38% Gilead Sciences, Inc.
Return on Equity 40.44% 40.66% Gilead Sciences, Inc.
Return on Assets (TTM) 10.29% 12.52% Gilead Sciences, Inc.
Free Cash Flow (TTM) $12.85B $9.46B Bristol-Myers Squibb Company
Dividend Yield 5.82% 2.57% Bristol-Myers Squibb Company
1-Year Return 14.83% 14.19% Bristol-Myers Squibb Company
Price-to-Sales Ratio (TTM) 2.50 5.62 Bristol-Myers Squibb Company
Enterprise Value $156.74B $181.31B Gilead Sciences, Inc.
EV/Revenue Ratio 3.25 6.16 Bristol-Myers Squibb Company
Gross Profit Margin (TTM) 67.23% 79.51% Gilead Sciences, Inc.
Revenue per Share (TTM) $24 $24 Bristol-Myers Squibb Company
Earnings per Share (Diluted) $3.46 $6.78 Gilead Sciences, Inc.
Beta (Stock Volatility) 0.27 0.40 Bristol-Myers Squibb Company
Short % of Float 1.54% 1.74% Bristol-Myers Squibb Company

Bristol-Myers Squibb Company vs Gilead Sciences, Inc. Stock Performance Analysis

Loading Price Chart...

BMY
GILD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bristol-Myers Squibb Company-1.56%1.21%-1.33%-5.81%3.59%5.20%
Gilead Sciences, Inc.-1.03%-2.97%-4.07%-14.40%3.77%2.22%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bristol-Myers Squibb Company14.83%-13.65%-14.05%-19.16%107.59%126.89%
Gilead Sciences, Inc.14.19%59.26%88.55%51.95%535.26%767.93%

Performance & Financial Health Analysis: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.

MetricBMYGILD
Market Information
Market Cap i$119.87B$165.87B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i8,535,0024,914,212
90 Day Avg. Volume i11,824,3575,711,564
Last Close$56.24$124.30
52 Week Range$42.52 - $62.89$104.46 - $157.29
% from 52W High-10.57%-20.97%
All-Time High$81.44 (Nov 28, 2022)$157.27 (Feb 11, 2026)
% from All-Time High-30.94%-20.96%
Growth Metrics
Quarterly Revenue Growth0.01%0.05%
Quarterly Earnings Growth14.10%0.22%
Financial Health
Profit Margin (TTM) i0.15%0.29%
Operating Margin (TTM) i0.28%0.37%
Return on Equity (TTM) i0.40%0.41%
Debt to Equity (MRQ) i254.98112.92
Cash & Liquidity
Book Value per Share (MRQ)$9.07$18.29
Cash per Share (MRQ)$5.24$7.74
Operating Cash Flow (TTM) i$14.16B$10.02B
Levered Free Cash Flow (TTM) i$11.15B$7.54B
Dividends
Last 12-Month Dividend Yield i5.82%2.57%
Last 12-Month Dividend i$3.11$3.98

Valuation & Enterprise Metrics Analysis: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.

MetricBMY (Apr 26, 2026)GILD (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i17.0619.66
Forward P/E i9.6113.85
PEG Ratio i0.010.85
Price to Sales (TTM) i2.505.62
Price to Book (MRQ) i6.517.29
Market Capitalization
Market Capitalization i$119.87B$165.87B
Enterprise Value i$156.74B$181.31B
Enterprise Value Metrics
Enterprise to Revenue i3.256.16
Enterprise to EBITDA i8.2012.44
Risk & Other Metrics
Beta i0.270.40
Book Value per Share (MRQ) i$9.07$18.29

Financial Statements Comparison: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBMY (2025)GILD (2025)
Revenue/Sales i48.20B29.44B
Cost of Goods Sold i13.94B6.23B
COGS % of Revenue i28.9%21.2%
Gross Profit i34.26B23.21B
Gross Margin i71.1%78.8%
Research & Development i9.95B5.80B
Operating Income (EBIT) i13.72B11.70B
Operating Margin i28.5%39.7%
EBITDA i19.95B14.81B
EBITDA Margin i41.4%50.3%
Pre-Tax Income i9.33B9.80B
Pre-Tax Income % of Revenue i19.4%33.3%
Income Tax i2.27B1.29B
Income Tax % of Revenue i4.7%4.4%
Net Income (Profit) i7.06B8.51B
Profit Margin i14.6%28.9%

Balance Sheet & Liquidity Metrics

MetricBMY (2025)GILD (2025)
Cash & Equivalents i10.21B7.56B
Total Current Assets i29.39B18.34B
Total Current Assets % of Revenue i61.0%62.3%
Total Current Liabilities i23.42B11.81B
Total Current Liabilities % of Revenue i48.6%40.1%
Long-Term Debt i44.68B22.13B
Long-Term Debt % of Revenue i92.7%75.2%
Total Shareholders Equity i18.51B22.62B
Retained Earnings i16.90B13.73B
Retained Earnings % of Revenue i35.1%46.6%
Property, Plant & Equipment i1.58B1.71B

Cash Flow Statement Comparison

MetricBMY (2025)GILD (2025)
Operating Cash Flow i14.51B10.19B
Operating Cash Flow % of Revenue i30.1%34.6%
Capital Expenditures iN/A-563.00M
Free Cash Flow i12.85B9.46B
FCF Margin i26.7%32.1%
Debt Repayment i-10.94B-1.79B
Common Stock Repurchase i0-1.92B

Short Interest & Institutional Ownership Analysis

MetricBMYGILD
Shares Short i31.50M21.52M
Short Ratio i2.293.56
Short % of Float i1.54%1.74%
Shares Outstanding i2.04B1.24B
Float Shares i2.03B1.24B
% Held by Insiders i0.09%0.13%
% Held by Institutions i83.86%92.71%
% Held by Public i16.05%7.16%

Dividend Analysis & Yield Comparison: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.

MetricBMYGILD
Last 12-Month Dividend i$3.11$3.98
Last 12-Month Dividend Yield i5.82%2.57%
3-Year Avg Annual Dividend i$2.60$3.35
3-Year Avg Dividend Yield i1.13%0.85%
3-Year Total Dividends i$7.79$10.06
Ex-Dividend DateJan 02, 2026Mar 13, 2026